Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments, including minoxidil, dermarolling, finasteride, dutasteride, hair transplants, hair systems, and shaving the head. The conversation covers various opinions on these treatments and mentions possible side effects as well as alternatives like wigs, vitamins, and lifestyle changes. The post expresses disappointment that there has been no major breakthrough in the field of hair loss treatments despite decades of research.

A user is concerned about starting finasteride due to negative reports and potential side effects. Other users suggest talking to a doctor, considering personal tolerance, and note that side effects are rare.

The user reversed male pattern baldness using a pro-thyroid diet, lifestyle changes, and scalp stimulation exercises, without Minoxidil or Finasteride. They reported reduced dandruff, itchiness, oiliness, and experienced hair regrowth and thickening over 15 months.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Considering adding Low Level Laser Therapy (LLLT) to a hair loss prevention regimen; discussing the effectiveness of LLLT, and evaluating double-blind random-controlled trials that have been conducted on laser combs.

Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

A recent publication suggests that the flavonoids eriocitrin and silymarin may be more effective than finasteride in binding to the enzyme responsible for hair loss. People in the conversation are skeptical about the effectiveness and safety of these flavonoids until tested on humans, and some discuss their personal experiences with other treatments.

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

The conversation discusses using ketoconazole, an anti-androgen, for hair loss and whether mesotherapy with dermarolling could enhance its absorption into the scalp. The user questions if the typical 2% ketoconazole shampoo dose would be effective when used after dermarolling to target androgen receptors in the scalp.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The conversation is about the potential side effects of using verteporfin in conjunction with a hair transplant. Specific treatments discussed include verteporfin, a hair transplant (HT), minoxidil (Min), finasteride (Fin), and RU58841 (RU).

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation discusses various treatments for hair loss, including minoxidil, finasteride, and topical dutasteride, with users debating their effectiveness and side effects. Despite the treatments, many believe androgenetic alopecia (AGA) ultimately prevails in the long term.

The conversation discusses the potential use of thermal paper receipts, which contain estrogen, as a treatment for hair loss. Participants humorously debate its effectiveness compared to established treatments like Minoxidil and finasteride.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

A user applied Minoxidil foam to their face to grow a beard and experienced increased hair density and darker hair as unintended benefits, despite initially using it for diffuse thinning on the scalp. Another person suggested that the user's heart rate increase might indicate a high conversion rate of Minoxidil to its active form, similar to taking oral Minoxidil.

This conversation is about how topical treatments for hair loss, such as Minoxidil and Finasteride, can be replaced by drinking oral versions of the same medications to achieve better results with less hassle. Some users have already been doing this with positive results.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

A user experienced severe side effects from using topical minoxidil sublingually, including muscle cramps, dizziness, and high potassium levels. They were advised to stop and seek medical help, emphasizing that topical minoxidil is not safe for ingestion due to its alcohol content.

The conversation discusses the potential benefits of castor oil for hair thickening, with one user noting it may increase prostaglandin E2 and decrease PGD2. The original poster plans to take 1-2ml orally daily.

The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.